Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Sales | 3,028,700 | 3,789,200 | 3,720,700 | 3,547,100 | 3,145,000 |
| Cost of Goods | 464,300 | 565,400 | 491,100 | 480,200 | 433,800 |
| Gross Profit | 2,564,400 | 3,223,800 | 3,229,600 | 3,066,900 | 2,711,200 |
| Operating Expenses | 1,973,000 | 2,234,001 | 2,050,200 | 1,997,500 | 1,960,600 |
| Operating Income | 591,700 | 990,200 | 1,179,500 | 1,069,600 | 751,400 |
| Interest Expense | 8,700 | 10,500 | 13,800 | 14,800 | 16,100 |
| Other Income | 322,000 | -21,600 | 327,300 | 573,300 | -34,600 |
| Pre-tax Income | 905,000 | 958,100 | 1,493,000 | 1,628,100 | 700,700 |
| Income Tax | 96,300 | 40,400 | 152,400 | 195,800 | -21,300 |
| Net Income Continuous | 808,700 | 917,700 | 1,340,600 | 1,432,300 | 722,000 |
| Net Income | $808,700 | $917,700 | $1,340,600 | $1,432,300 | $722,000 |
| EPS Basic Total Ops | 7.58 | 8.55 | 12.40 | 13.25 | 6.70 |
| EPS Basic Continuous Ops | 7.58 | 8.55 | 12.40 | 13.25 | 6.70 |
| EPS Diluted Total Ops | 7.27 | 8.12 | 11.54 | 12.41 | 6.27 |
| EPS Diluted Continuous Ops | 7.27 | 8.12 | 11.54 | 12.41 | 6.27 |
| EPS Diluted Before Non-Recurring Items | 6.43 | 9.90 | 11.73 | 10.10 | 7.97 |
| EBITDA(a) | $718,600 | $1,116,599 | $1,301,200 | $1,190,300 | $865,500 |